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Treatment refusalBackground: Cancer is a disease that affects mostly older adults. Older adults often have other chronic
health conditions in addition to cancer and may have different health priorities, both of which can impact
cancer treatment decision-making. However, no systematic review of factors that inﬂuence an older can-
cer patient’s decision to accept or decline cancer treatment has been conducted.
Materials and methods: Systematic review of the literature published between inception of the databases
and February 2013. Dutch, English, French or German articles reporting on qualitative studies, cross-
sectional, longitudinal observational or intervention studies describing factors why older adults accepted
or declined cancer treatment examining actual treatment decisions were included. Ten databases were
used. Two independent reviewers reviewed manuscripts and performed data abstraction using a stan-
dardized form and the quality of studies was assessed with the Mixed Methods Appraisal Tool.
Results: Of 17,343 abstracts reviewed, a total of 38 studies were included. The majority focused on breast
and prostate cancer treatment decisions and most studies used a qualitative design. Important factors for
accepting treatment were convenience and success rate of treatment, seeing necessity of treatment, trust
in the physician and following the physician’s recommendation. Factors important for declining cancer
treatment included concerns about the discomfort of the treatments, fear of side effects and transporta-
tion difﬁculties.
Conclusion: Although the reasons why older adults with cancer accepted or declined treatment varied
considerably, the most consistent determinant was physician recommendation. Further studies using
large, representative samples and exploring decision-making incorporating health literacy and comorbid-
ity are needed.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction number of older adults diagnosed with cancer. It is estimated thatCancer is a signiﬁcant health problem in older persons. With the
aging of the population there will be a considerable increase in the42% of all incident cases and over 60% of mortality due to cancer
occur in persons aged 70 and over [1,2].
Older persons with cancer are under-represented in clinical tri-
als, especially frail older persons with co-morbidities, leading to
gaps in knowledge around optimal treatment [3–5]. Older adults
who are included in clinical trials may not be representative of
older adults with cancer in general. Research has shown that older
adults suffering from cancer have been under-investigated and
under-treated [6–9]. Cancer-directed treatment options have
changed in recent years and more ‘‘elderly-friendly’’ treatments
have been developed (e.g. oral single-agent chemotherapy)
Titles and abstracts retrieval from the 10 databases: 
17,343 abstracts retrieved from the electronic databases 
Abstracts excluded: 16,798. Reasons: 
198 M.T.E. Puts et al. / Cancer Treatment Reviews 41 (2015) 197–215[10–13]. The older population is very heterogeneous with regard to
health, functional, psychological, social, cultural and economic sta-
tus. Physiologic functions such as renal, cardiac and pulmonary
function decline with age, and these inﬂuence the risks and bene-
ﬁts of treatment. Studies have shown that there is more variation
in treatments offered (including therapeutic adaptations and num-
ber of treatments offered) by cancer specialists to adults with
increased age and declining health, suggesting increasing difﬁculty
in identifying and recommending the most appropriate treatments
in this population [14–17]. The treatment decision for older adults
can be difﬁcult, as older adults often have other diseases in addi-
tion to cancer. These other diseases can impact on life expectancy,
treatment effectiveness as well as treatment tolerability. Beyond
comorbidities, other factors may inﬂuence treatment decisions dif-
ferently in older adults compared to younger adults; older adults
have different social support systems, sensory impairment,
changes in cognition, lower levels of education, and possibly lower
levels of health literacy which can all affect treatment decision-
making. In addition, older adults may have different priorities than
younger adults (e.g. less willing to trade quality of life for survival
prolongation [18].
Refusal of recommended therapy and underuse of treatment
have been shown to be more common in older adults and these
have been shown to lead to negative outcomes, such as increased
cancer recurrence rates and poorer survival rates which have been
studied most extensively in older women with breast cancer
[8,19,20]. There have been several studies examining older adults’
decision-making processes and reasons for refusing cancer treat-
ment, and several narrative reviews of treatment decision-making
[21–23], as well as a recent review by Tariman et al. [24] that
focused on decision-making models in cancer treatment deci-
sion-making. However, until now no systematic review of factors
inﬂuencing older cancer patients’ decisions to accept or decline
cancer treatment has been performed. Understanding these factors
is of clinical relevance to health care professionals trying to
enhance treatment adherence, reduce errors, and improve out-
comes. Gaps in current understanding are also important to iden-
tify as they can inform future research. Therefore, we conducted
a systematic review with the primary objective of synthesizing
all factors inﬂuencing older adults’ decisions to accept or decline
cancer treatment proposed by their physicians. In particular, we
were interested to determine if the factors inﬂuencing older adults’
decisions to accept or decline cancer treatment varied by cancer
stage, cancer type, cancer treatment, and age (younger old (65-
74) and older old (75+)).Duplicates: 4,139 
Not about reasons why cancer treatment was 
accepted/refused or did not provide data specifically in older 
adults (mean age 65 or older): 12,396 
Review/editorial/expert opinion: 263 
Full text articles read: 545 
Abstracts excluded: 490. Reasons: 
Not about reasons why cancer treatment was 
accepted/refused or did not provide data specifically in older 
adults (mean age 65 or older): 454 
Review/editorial/expert opinion: 36 
55 Full text articles selected reporting on 51 unique studies  
40 publications reporting on 38 
studies examining actual cancer 
treatment decisions of the older study 
participants included in this review 
15 publications reporting on 12 
studies examining hypothetical cancer 
treatment decisions of the older study 
participants (results will be published 
separately) 
Fig. 1. Flow chart of study selection.Materials and methods
Search strategy and selection criteria
This review was based on a systematic, comprehensive search
of ten databases from inception to February 2013 including the
Cochrane Central Register of Controlled Trials (CENTRAL), MED-
LINE, EMBASE, Cumulative Index to Nursing and Allied Health
(CINAHL), Allied and Complementary Medicine (AMED), Psych-
INFO, Ageline, Sociological Abstracts, Web of Science, and Applied
Social Sciences Index and Abstracts (ASSIA) databases. A study
was eligible for inclusion if it reported on reasons why older adults
with cancer (i.e. mean age study population 65 years or over or if
the study mean/median age was <65 but reported results on a sub-
group analysis of older adults with a mean/median ageP 65)
accepted or declined cancer treatment and were published in Eng-
lish, Dutch, French or German. Study designs could be quantitative
or qualitative, cross-sectional or longitudinal. Editorials, case stud-
ies, reviews, expert opinion papers and studies that were publishedas abstracts only were excluded from the review. The following
sets of keywords or free text words were used in combination with
subject headings where available: cancer (including the keywords/
subject headings and free text words including cancer, neoplasm,
oncology, etc. all combined with OR) AND aged 65 and older
(including the keywords/subject headings aged, geriatrics, older
adults, elderly etc. all combined with OR) AND decision making
(including the keywords/subject headings decision making, choice
behavior, patient acceptance of health care, patient participation,
treatment refusal, etc. all combined with OR). See Appendix A for
the search strategy as used in Ovid Medline. The literature search
was performed by an experienced university librarian.
The ﬁnal studies included in this review were selected in two
steps (see Fig. 1). During the initial study selection process, two
independent reviewers selected manuscripts for subsequent full
text review based on their titles and abstracts. When at least one
reviewer was uncertain about whether the article fulﬁlled the
inclusion criteria, it was included for full-text review. In the second
selection step, the full-text articles were reviewed independently
by the same authors. Disagreements between reviewers were
resolved by consensus (this process was used for eight studies).
If multiple articles reported similar results, only the article with
the most complete information was retained. For all articles for
which no mean/median age was reported, we contacted the study
authors to obtain details on age. If no response was received after
at least three attempts, the articles were not included.
We also reviewed the reference lists of all selected articles to
identify any additional relevant articles, but no additional studies
were identiﬁed. When an article referred to additional publications
for more details concerning study methods and design, those pub-
lications were also acquired.
During the data abstraction process it became clear that the
studies examining factors inﬂuencing acceptance or refusal of rec-
ommended cancer therapy using the actual treatment situation of
the study participants (e.g. reﬂecting on why they had made the
treatment decisions they had for their cancer until the time of
the study) were conceptually and methodologically distinct from
those examining cancer patients who were presented with a
hypothetical cancer treatment situations and were asked to make
M.T.E. Puts et al. / Cancer Treatment Reviews 41 (2015) 197–215 199treatment decisions while imagining having this cancer (i.e. the
participant could be asked to make a cancer treatment decision
for a different cancer diagnosis and stage than their own diagno-
sis). Thus, considering the large amount of data and methodologi-
cal differences, it was decided to separate the review results into
two papers and results concerning hypothetical decision-making
will be summarized in a separate paper.Data abstraction
The same reviewers who performed the article selection pro-
cess conducted independent data abstraction. The abstracted infor-
mation included study design, aim of study, location of study,
sampling method, source of data, recruitment type and timeline,
characteristics of study participants, details on cancer diagnosis
and treatment, details on how reasons for accepting/declining can-
cer treatment were collected, and details of statistical analysis,
source of funding and whether or not authors had declared any
conﬂict of interest. If any aspect of the study design was unclear,
the authors of the study were contacted.Quality assessment
Both quantitative and qualitative studies were included in the
review. To determine the quality of the individual studies included
in the review, two reviewers (MP and BT) independently scored
studies using the Mixed Methods Assessment Tool (MMAT) [25]
which can be used for mixed methods research and mixed studies
reviews (MSR). The reliability of the MMAT [25] was tested by the
scoring system’s developers, and inter-rater reliability was found
to be moderate to excellent. The tool was also found to be very
user-friendly. The 2011 MMAT scoring system contains ﬁve types
of mixed methods study components or primary studies in a
MSR context, each with its own set of methodological quality cri-
teria based on existing published criteria. For each item the answer
categories were ‘yes’, ‘no’, or ‘can’t tell’ followed by comments. The
ﬁve types of mixed methods study components or primary studies
included in the MMAT are (1) qualitative; (2) quantitative random-
ized controlled trials; (3) quantitative non-randomized; (4) quanti-
tative descriptive; and (5) mixed methods. No study was excluded
based on the quality assessment as we wanted to provide an
overview of all factors important to older adults reported in the
literature.Results
We reviewed 17,343 titles and abstracts for eligibility in the
ﬁrst step in which we selected (see Fig. 1). Fifty-ﬁve manuscripts
reporting on 51 unique studies were selected; 40 publications
reporting on 38 unique studies examined factors inﬂuencing the
older adult’s decision to accept or decline treatment examining
the actual cancer treatment decision taken by the study participant
and are included in this manuscript [19,26–64], the 12 other stud-
ies examined hypothetical treatment decisions and will be
reported separately. The percentage identiﬁed below refers to the
total of 38 studies in the results section. In four manuscripts, there
were two publications reported on the same qualitative study but
reporting new results, and thus both manuscripts were included
for both studies [26–29]. All but two of the included manuscripts
were written in English, the other two were written in French
[28,29].Quality assessment
The quality of the studies ranged from poor to good but was
moderate for most studies, see Table 1. We tried to contact study
authors of most studies to get additional information on study
methods used, but as many studies had been published a while
ago when reporting standards were less clear, for most studies
one or more aspects of the methodology used were not described
in sufﬁcient detail. For the qualitative studies, there was little
information provided on the data analysis, the context in which
the data were collected and the interaction between researcher
and participants [28,29,32–34,36,39,42,48–50,52,54,59,63]. For
the quantitative studies (n = 20), response rates were not reported
(40%) or were below 60% (10%), the sample strategy method was
unclear (20%), the measurement instrument used was newly
developed and no information was provided on the psychometric
properties for this new tool [19,30,31,37,38,41,44,45,47,51,53,
57,58,60,61].
Characteristics of the included studies
Characteristics of the included studies are shown in Tables 2 and
3. Eighteen studies used a qualitative study design [28,29,32–
36,42,43,48–50,52,54,59,63–65], eight studies used a retrospective
observational design [19,30,38,44,46,51,53,55], seven studies used
a cross-sectional observational design [45,47,58,60–62], and ﬁve
studies used a prospective observational design [31,37,40,41,57].
Almost all studies used primary data collection [26–29,31–33,35–
50,52–54,57–60,63–65] or retrospective chart reviews and/or
administrative databases [19,30,51,55,61]. Two studies used ran-
dom sampling techniques [37,38], ﬁve used consecutive sampling
techniques [41,53,57,60–62], four studies used convenience sam-
pling techniques [34,42,56,58], 13 studies used purposive/other
qualitative sampling techniques [26,27,32,33,35,36,39,43,49,
50,52,54,59,63,64], four studies used other methods [19,46,51,55]
and nine studies [28–31,40,44,45,47,48] did not describe the sam-
pling methods used. Sample sizes in the studies using qualitative
methodologies ranged from six [33] to 102 [48] and the response
rate varied from 12.5% [34] to 100% [54] and was not reported for
ﬁve studies. The sample sizes for studies using quantitative meth-
odologies ranged from 20 [40] to 5339 [19] and the response rate
varied from 57% [44] to 90% [37] and was not reported for eight
studies.
The characteristics of treatment decisions studied
See Tables 2 and 3 for the description of the studies and Tables 4
and 5 for a description of the treatments studied. For 19 studies it
was not reported if cancer patients had received cancer treatment
prior to the time the study was conducted [19,26–30,
33,34,36,38,46,49,51,53–55,57,59,63,64], in nine studies partici-
pants had not yet received cancer treatment [31,35,37,39–41,
44,45,60], and in ten studies some or all participants had already
received treatment [32,42,43,47,50,52,56,58,61,62]. For the ﬁve
quantitative studies which reported the number of study partici-
pants declining treatment, it varied between 0% [31,41,44,45] and
50% [51]. In six qualitative studies the percentage of participants
that declined treatment varied between 0% [39,48,50,52] to 100%
[59,64] (these studies focused on reasons for decline only).
In terms of what treatment-decision making was studied, one of
38 studies focused on the treatment decision making process for
cancer in general in participants with mixed cancers [26,27]. Two
studies focused on a speciﬁc cancer treatment [28–30] (i.e. surgery
or chemotherapy) for patients with mixed cancers. One study
focused on cancer treatment decisions without specifying the type
of cancer treatment in participants who had cancer but the type of
Table 1
Quality assessment using the Mixed Methods Appraisal Tool.a
First author & year
published
Type of study Screening questions: Qualitative Quantitative descriptive
A. Are there clear
qualitative and
quantitative
research questions,
or a clear mixed-
methods research
question?
B. Do the
collected
data
address the
research
question?
1.1 Are the
sources of
qualitative
data relevant
to address
the research
question?
1.2 Is the Process
for analyzing
qualitative data
relevant to
address
research
question?
1.3 Is appropriate
consideration given
to how ﬁndings relate
to the context in which
data were collected?
1.4 Is appropriate
consideration given
to how ﬁndings relate to
researchers’ inﬂuence
through interaction with
participants?
4.1 Is the
sampling
strategy
relevant to
address the
research
question?
4.2 Is the
sample
representative
of the
population
under study?
4.3 Are
measurements
appropriate (clear
origin, or validity
known, or standard
instrument)?
4.4 Is there
an
acceptable
response
rate (60%
or above)?
Anchisi [29]b Qualitative No Yes Can’t tell Can’t tell Can’t tell Can’t tell
Anchisi [28]b Qualitative Yes Can’t tell Can’t tell Can’t tell Can’t tell Can’t tell
Ashley [30] Cross-
sectional
Yes Yes Yes Yes Can’t tell Yes
Cassileth [31] Cohort Yes Yes Can’t tell Can’t tell Yes Can’t tell
Chapple [32] Qualitative Yes Yes Yes Can’t tell Yes Yes
Chouliara [33] Qualitative Yes Yes Yes Yes Yes Can’t tell
Ciambrone [34] Qualitative Yes Yes Yes Yes Yes Can’t tell
Cohen [35] Qualitative Yes Yes Yes Yes Yes Yes
Crooks [36] Qualitative Yes Can’t tell Can’t tell Yes Can’t tell Can’t tell
Cykert [37] Cohort Yes Yes Can’t tell Can’t tell Yes Can’t tell
Cyran [38] Retrospective
Observational
Yes Yes Can’t tell Can’t tell Yes No
Davison [39] Qualitative Yes Yes Yes Yes Yes Can’t tell
Denberg [40] Qualitative Yes Yes Yes Yes Yes Yes
Diefenbach [41] Cohort Yes Yes Can’t tell Can’t tell Yes Yes
Docherty [42] Qualitative Yes Yes Yes Yes Yes Can’t tell
Elit [43] Qualitative Yes Yes Yes Yes Yes Yes
Gorin [44] Cohort Yes Yes Can’t tell Can’t tell Can’t tell No
Gwede [45] Cross-
sectional
Yes Yes Can’t tell Can’t tell Can’t tell Yes
Hall [46] Cross-
sectional
Yes Yes Yes Yes Yes Yes
Hardy [47] Cross-
sectional
Yes Yes Yes Can’t tell Yes Can’t tell
Holmboe [48] Qualitative Yes Yes Yes Yes Yes Can’t tell
Husain [49] Qualitative Yes Yes Yes Yes Yes Can’t tell
Kreling [50] Qualitative Yes Yes Yes Yes Yes Can’t tell
Lim [51] Retrospective
Cohort
Yes Yes Can’t tell Can’t tell Can’t tell Yes
O’Rourke [52] Qualitative Yes Yes Yes Yes Yes No
Petrisek [53] Retrospective
Cross-
sectional
Yes Yes Yes Yes Can’t tell Yes
Pieters [54] Qualitative Yes Yes Yes Yes Yes No
Richert-Boe [55] Retrospective
Cohort
Yes Yes Yes Yes Can’t tell Yes
Sanders [56] Qualitative Yes Yes Yes Yes Yes Yes
Sandison [57] Prospective
Cohort
Yes Yes Yes Yes Can’t tell Can’t tell
Schulman [58] Cross-
sectional
Yes Yes Can’t tell Can’t tell Can’t tell Can’t tell
Sharf [59] Qualitative Yes Yes Yes Yes Yes No
Sinding [27]c Qualitative Yes Yes Yes Yes Yes Yes
Sinding [26]c Qualitative Yes Yes Yes Yes Yes Yes
Tang [60] Cross-
sectional
Yes Yes Yes Yes Yes Can’t tell
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M.T.E. Puts et al. / Cancer Treatment Reviews 41 (2015) 197–215 201cancer of the participants was not reported [33]. The other 34 stud-
ies focused on treatment decisions in a particular type of cancer.
Eighteen studies focused on treatment decisions for prostate can-
cer; 12 for early/localized prostate cancer [32,35,39–41,44–
46,52,55,62,63] and three for advanced/metastatic prostate cancer
[31,47,48] and three on treatment for all stages of prostate cancer
[42,58,64]. Ten studies focused on breast cancer treatment deci-
sions; six on early stage [38,49,53,54,57,61], none on advanced
stage, and four were on breast cancer treatment in general or a par-
ticular breast cancer treatment [19,34,36,50]. There were three
studies focused on treatment decisions for lung cancer
[37,59,60], one for recurrent ovarian cancer [43], and two for colo-
rectal cancer [51,56].
Reasons why older cancer patients accepted the recommended cancer
treatment
See Tables 4–6 for a complete overview of reasons why older
adults accepted the recommended treatment. Reasons included
treatment convenience (16 studies), expectations about side effects
(16 studies), treatment success rates (14 studies), being aware of the
disease and prognosis (treatment is considered necessary to live,
wanting to get rid of disease) (14 studies), trust/faith in the doctor
(13studies), treatmentexperiencesof signiﬁcantothers (13studies),
physician’s advice/recommendation (12 studies), wanting to live as
long as possible and/or continue current lifestyle (7 studies), previ-
ous positive personal treatment/hospital experiences (6 studies),
information received about the treatment (4 studies), and family
support (2 studies). The reasons for acceptance were fairly similar
across qualitative and quantitative studies, see Table 6.
Reasons why older cancer patients declined the recommended cancer
treatment
See Tables 4–6 for a complete overview of all reasons why older
adults declined recommended cancer treatments. Reasons for
decline included fear of side effects (16 studies), unclear beneﬁts
of treatment (7 studies), having seen family members and friends
experience side effects of treatment (7 studies), feeling high risk
for treatment due to comorbidities/other medical issues (7 stud-
ies), feeling too old for treatment, current quality of life and com-
fort most important at their age (6 studies), belief in non-
conventional treatments (4 studies), ﬁnancial reasons (4 studies),
distrusting physician/poor communication with physician/lack of
information about the treatment (3 studies), transportation
issues/travelling needed for treatment (3 studies), and side effects
of treatment would make them dependent/burden on others 3
(studies), negative personal treatment experiences (2 studies).
The reasons for decline were fairly similar across qualitative
and quantitative studies, see Table 6.
Results of studies comparing different treatment options for one type
of cancer
The studies focused on early stage prostate cancer comparing
the different treatment options such as surgery, radiation, active
surveillance/watchful waiting showed that important reasons for
participants choosing surgery over other treatments included
wanting to do something [32], best chance of cure [41,48], positive
treatment experience of friends and family [41]. For choosing
brachytherapy, reasons included minimal side effects and local
treatment [40,46,63], less invasive and more convenient than sur-
gery [41,48]. For participants choosing active surveillance/watch-
ful waiting, reasons included trust in the physician [39], fear of
incontinence or impotence, and lack of scientiﬁc evidence that
other treatment options are better [32,39,44,48].
Table 2
Description of the qualitative studies.
First author & year
published
Country Study aim Sample size &
response rate
Mean/median age,
years SD (range)a
%
Women
Type of cancer & stage
Anchisi [29]b France To explore the process of patient’s choice including
goals, resources and constraints
21
66%
Median age women
76.5 (range 70–83)
men 71.5 (range
70.3–75)
57 Mixed cancers
All stages
Anchisi [28]b France To explore psychosocial factors that impact the
chemotherapy decision
21
66%
Median age women
76.5 (70–83) men
71.5 (70.3–75)
57 NR
NR
Chapple [32] UK To explore how men with prostate cancer make the
decision to accept or decline watchful waiting
recommended for their early prostate cancer
50
NR
(71–85) 0 Prostate
All
Chouliara [33] UK To explore treatment decision making in older people
with cancer
6
NR
(65–96) 67 NR
NR
Ciambrone [34] USA To identify factors associated with primary therapy
decision-making and how support persons inﬂuence
women’s choices
30
12.5%
Mean 77 100 Breast
NR
Cohen [35] UK To explore the treatment decision-making experience
of recently diagnosed men with early-stage prostate
cancer
19
NR
Mean 74.42 0 Prostate
Early (Stages 1 & 2)
Crooks [36] Canada To explore how older women live with breast cancer,
integrate cancer into their lives and understand these
experiences
20
NR
(66–94) 0 Breast
Early (Stages 1 & 2)
Davison [39] Canada To identify and describe how men decided to go on
active surveillance for their prostate cancer
25
56%
Mean 66 0 Prostate
Early (Stage 1 & 2)
Denberg [40] USA To examine how men from working and middle-class
make treatment decisions for localized prostate cancer
(Veterans hospital patients)
20
NR
Mean 65 (54–80) 0 Prostate
Early (Stage 1 & 2)
Docherty [42] UK To examine the impact of patient knowledge and
awareness of prostate cancer on their medical process
from initial symptom presentation to post treatment
9 patients and
3 spouses
NR
Mean age of patients
and their wives 71
0 for
patients
Prostate
NR
Elit [43] Canada To explore the treatment decision making process of
women with recurrent ovarian cancer
26
67%
Mean 69 100 Ovarian
Advanced (Stage 2–4)
Holmboe [48] USA To identify what factors men consider important when
choosing treatment for prostate cancer and to assess
why men reject active surveillance as a treatment
option
102
96%
Mean 66.4 0 Prostate
Early (Stage 1 & 2)
Husain [49] UK To examine why women aged 70 years and older chose
primary endocrine therapy or surgery for breast cancer
21
70%
Mean 83.4 100 Breast
Early (Stage 1 & 2)
Kreling [50] USA To examine attitudes of older breast cancer patients
toward chemotherapy and the factors that inﬂuences
their decision to accept or decline this treatment
modality
34
NA
NR sample aged 65
or older
100 Breast
Non-metastatic
O’Rourke [52] USA To examine how newly diagnoses prostate cancer
patients and their spouses make initial treatment
selections
18 couples
95%
Mean patients 67.6,
wives younger
0 for
patients
Prostate
Early (Stage 1 & 2)
Pieters [54] USA To understand how older women aged 70 and over
who have received early breast cancer treatment had
experienced treatment decision-making
18
100%
Mean 76 100 Breast
Stages I–III
Sanders [56] UK To explore which factors inﬂuenced patient
involvement in the treatment decision-making process
49
observations
NR
Subgroup older
patients 65–
80 years
33 Colorectal
Duke B, C, D
Sharf [59] USA To examine why patients declined further
recommendations for diagnosis or treatment of lung
cancer
9
43%
Mean 69.6 (48–80) 0 Lung
Of the seven patients
with a conﬁrmed
diagnosis, none had
brain metastases
Sinding [27]c Canada To examine how older age affects cancer care from the
perspectives of older women
15
35%
NR, all > 70 100 Breast & Gynecologic
No evidence of
metastatic disease
Sinding [26]c Canada To examine how older women with cancer make
treatment decisions and how this is inﬂuenced by
social locations
15 older adults
and 4 health
care
professionals
40%
NR, all > 70 100 Breast & Gynecologic
NR
Ward-Smith [63] USA To explore the impact of brachytherapy on quality of
life
7
78%
Mean 69.5 0 Prostate
Localized
White [64] Canada To examine why men with prostate cancer declined
conventional treatment and choose CAM
29
67%
Mean 67.5 0 Prostate
NR
NR = not reported, NA = not applicable.
a If mean/median age was available this information is reported with SD but if not the age data that was available from the study is reported.
b Anchisi [28,29] reports on the same study.
c Sinding [26,27] reports on the same study.
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Table 3
Description of the quantitative studies.
First author & year
published
Country Study design Study aim Sample size & response rate Mean/Median age, years SD (range)a %
Women
Type of cancer
& stage
Ashley [30] USA Retrospective
observational
To evaluate the effect of our preoperative protocol and
patient selection on the relative frequency of continent
urinary diversion and incontinent urinary diversion in
patients treated with radical cystectomy
200
NA
Mean age 66 (14–91) 21 Mixed
NR
Cassileth [31] USA Prospective
observational
To explore the feasibility of offering patients the
opportunity to select their own treatment
147
NR
Median age patients on goserelin 69
(48–96), median age orchiectomy
patients 71 (53–85)
0 Prostate
NR
Cykert [37] USA Prospective
observational
To identify potentially modiﬁable factors re surgery in
early-stage lung cancer and to explore why blacks
undergo surgery less often
386
90%
Mean 66 44 Lung
Early (Stages 1
& 2)
Cyran [38] USA Retrospective
observational
To describe factors associated with the type of surgical
procedure performed in older women with early-stage
breast cancer
198
58%
Mean 72 100 Breast
Early (Stage 1 &
2)
Diefenbach [41] USA Prospective
observational
To examine treatment decision-making among men
with early prostate cancer
654
72%
Mean 66 0 Prostate
Early (Stage 1 &
2)
Gorin [44] USA Retrospective
observational
To study why patients on Active Surveillance had
selected this treatment option
105
57%
Mean 65.5 0 Prostate
Early (Stage 1 &
2)
Gwede [45] USA Cross-
sectional
To examine the treatment decision-making process in
men with early prostate cancer and which demographic,
clinical, cognitive and affective factors were associated
with the treatment selected?
119 (67 with brachytherapy
and 52 with radical
prostatectomy) 84%
Mean study age 62 but for patients in
the subgroup brachytherapy 65.2
0 Prostate
Early (Stage 1 &
2)
Hall [46] USA Retrospective
observational
To examine if patients would choose the same treatment
again
262
75%
Radical prostatectomy group mean
62, Brachytherapy only mean 66,
brachytherapy in combination with
external radiotherapy mean 70
0 Prostate
T1c–T3
Hardy [47] USA, UK, France, Spain,
Italy, Germany
Cross-
sectional
To explore the attitudes of men with locally advanced or
metastatic prostate cancer toward diagnosis and
treatment
382
NR
36% were aged 61–70, 34% aged 71–
80 and 9% 81 years and older
0 Prostate
Locally
advanced and
metastatic
Lim [51] Australia Retrospective To examine long-term outcomes of elderly patients
treated with RT or chemo radiation
48
NA
Median 76 (49–94) 27 Rectal
TI–III
Petrisek [53] USA Retrospective
observational
To understand how older women with early-stage breast
cancer made the treatment decision and gain better
insights into age-related differences
179
84%
NR 100 Breast
Stages I–IIIa
Richert-Boe [55] USA Retrospective
observational
To determine whether differences existed in prostate
cancer treatments received by White and African
American men at a Health Maintenance Organization
and to determine the reasons for these differences
237
NA
Mean 66 years at diagnosis for
African American, mean 68 for white
at diagnosis
0 Prostate
Stages I–III
Sandison [57] UK Prospective
observational
To examine treatment preference for breast cancer in
women aged 70 years and older
50
NR
NR, sample > 70 100 Breast
Stages I–III
Schulman [58] Germany, Italy, Spain,
Netherlands, France
Cross-
sectional
To examine patient beliefs as barrier for optimal
management of their disease in men with prostate
cancer
200
NR
Mean 70.1 0 Prostate
NR (Patients
had to be
receiving LHRH
agonist
treatment)
Tang [60] Singapore Cross-
sectional
To examine patients preference of radiation treatment
schedules
92
NR
Mean 68 15 Lung
Advanced
(Stage 2–4)
Tang [61] UK Cross- To proﬁle older women with operable breast cancer and 268 Mean 78.5 100 Breast
(continued on next page)
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over lumpectomy showed that fear of recurrence, wanting to have
treatment completed and physician recommendation were impor-
tant [38,49]. Reasons for choosing lumpectomy over mastectomy
included keeping the breast, equivalent survival and physician rec-
ommendation [38]. A study comparing surgery to primary endo-
crine therapy (PET) showed that reasons for choosing surgery
included positive personal experiences or for important others
with surgery, whereas reasons for choosing PET included having
had painful biopsies and wanting to carry on life as before [49].
A study comparing surgery, radiation and chemotherapy showed
that patients chose PET for feelings of unﬁtness for surgery and
having no time for surgery. Those who declined all treatment felt
asymptomatic, and too old or high risk due to comorbidities [61].
Factors reported to have no impact on the decision in individual
studies
In one or more studies, factors such as previous medical condi-
tions [39], side effects of treatment [29,33,40,43], support of
friends/family [29,33], support of the family physician [29], age
of the patient [29] had no impact on the treatment decision.
Studies comparing the treatment decision making process in young old
vs. older old
This was explored in seven studies and one study reported no
differences based on age [49]. Two studies reported that younger
patients with prostate cancer chose surgery more often than older
patients [41,52]. Schulman studied reasons for choosing hormonal
treatment for prostate cancer in patients who were all receiving
luteinizing hormone-releasing hormone (LHRH) agonist (80%
receives an injection every three months and the other 20%
monthly) and showed that younger patients preferred hormonal
treatment with less frequent injections due to having fewer
reminders of the disease, and less discomfort and less impact on
daily life compared to older men [58]. Chapple et al [32] reported
that younger patients felt pressured by surgeons to have surgery
instead of watchful waiting for prostate cancer, whereas this was
not reported by older participants. Tang et al [61] studied breast
cancer treatment decisions and showed that older patients felt
unﬁt to undergo treatment; whereas this was not reported by
younger patients. The study by Petrisek et al showed that for the
group of older women with breast cancer, fear of recurrence, phys-
ical aspects of the treatment and everyday responsibilities in life
were signiﬁcantly less important compared to the younger old
women [53].
Were there differences in reasons for accepting or declining by cancer
stage?
Only one study by van Tol-Geerdink [62] studied participants
with high risk and low risk prostate cancer and reported that those
with a better prognosis/low risk disease were more likely to choose
low dose RT instead of high dose RT compared to patients with
poorer prognosis/high risk disease.Discussion
To our knowledge, this is the ﬁrst systematic review focusing on
reasons why older adults with cancer accept or decline cancer
treatments. The results showed that important factors in the deci-
sion to accept or decline the recommended cancer treatment
included the physician’s recommendation, trust in the physician,
communication with the physician, expectations about side effects
Table 4
Factors associated with cancer treatment decline or acceptance in qualitative studies.
First author & year
published
Previous
treatment
received
Type of treatment
studied
Type of analysis
used
Percentage/number
declining treatment
Factors associated with decline of
treatment
Factors associated with
acceptance of treatment
Other factors studied but not
important for acceptance or
refusal
Anchisi [29]a NR Chemotherapy and for
some chemo radiation
NR 14% NR Older adults accepted treatment
because of their awareness of the
disease and prognosis, their
discussion with the oncologist
about the aim and side-effects of
treatment and the possibility to
stop the treatment
Side effects, support of the family
and family physician, age of the
patient
Anchisi [28]a NR Chemotherapy and for
some chemo radiation
NR 14% Transportation difﬁculties was a
reason for refusal
The will to live was a strong
motivation for receiving
treatment, as was having family
support to undergo treatment, the
treatment was seen as necessary
to live and therefore accepted
NR
Chapple [32] Some
participants
were
diagnosed
many years
ago with
experience
with a wide
range of
treatments
Watchful waiting Qualitative
methods, not
further speciﬁed
NR Wanted to do something positive
& ﬁx the problem, had seen what
cancer had done to others and
were afraid of the consequences of
any delay, pressure from families
to pursue active treatment
Avoidance of incontinence and
impotence, worry about the side
effects of treatment, scientiﬁc
evidence that physicians don’t
really know whether outcomes of
treatments are more positive
NR
Chouliara [33] NR NR Framework
analysis
NR If side effects would make them a
burden on their loved ones
Participants wanted as much
treatment as they could receive as
they wished to prolong their life
as much as possible with average
quality of life (which meant
enjoying life, no severe pain,
cancer, no disruption in normal
life) and if treatment is effective
for their disease and physical
status, and if still offered, and if
they are able to physically and
cognitively able to tolerate it,
belief in the effectiveness of
treatment, not wanting to become
a burden by leaving their illness
untreated, following the doctor’s
advice, being optimistic and
expecting things to improve over
time
Signiﬁcant others had no impact.
Side effects were seen as an
unavoidable and necessary part of
treatment by some
Ciambrone [34] NR All breast cancer
treatments
Grounded theory
methodology
Some participants
declined, but exact
number declining
NR
Older women did not want chemo
or radiation as they felt that
comfort and quality of life was
more important than extending
their lives, the potential side
effects were not worth it at their
age, not being convinced of
chemo/rad efﬁcacy, knowing
friends that had had chemo/rad
The need for travelling every day
to the hospital for treatment
Most women followed the advice
of the physician, getting rid of
cancer was the ﬁrst priority.
Women who choose the
treatment themselves also wanted
to get rid of the cancer and most
chose treatment on the basis of
the treatments they wished to
avoid because of side effects or
experiences of others with that
treatment. Women had trust in
NR
(continued on next page)
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Table 4 (continued)
First author & year
published
Previous
treatment
received
Type of treatment
studied
Type of analysis
used
Percentage/number
declining treatment
Factors associated with decline of
treatment
Factors associated with
acceptance of treatment
Other factors studied but not
important for acceptance or
refusal
their physician and therefore
accepted the treatment decision
Cohen [35] No Surgery, watchful
waiting, radiation
therapy and hormonal
therapy
Qualitative
analysis not
further speciﬁed
NR NR Faith in doctors; physician
decided treatment
NR
Crooks [36] NR Surgery, radiation
therapy and
chemotherapy
Grounded theory
methodology
NR Those who had parents and
spouses who had received
chemotherapy were more likely to
decline the treatment as a result
of these experiences
NR NR
Davison [39] No Active surveillance Phenomenology 0% Reasons for declining active
prostate cancer therapy and
choosing active surveillance:
potential for impotency,
incontinence, chances of
developing side effects and advice
from friends about side effects.
One person on active surveillance
wanted to go off due to the
perceived seriousness of the
disease, if it was cancer it should
be treated
When the different specialist
recommendations concurred and
when specialists were highly
renowned or published, it was
easier to follow advice
Previous medical conditions did
not inﬂuence how men perceived
their ability to undergo active
treatment
Denberg [40] No Radical prostatectomy,
external beam radiation
therapy, brachytherapy,
hormonal therapy and
watchful waiting
Grounded theory
methodology
NR Treatment success and side effects
only evident at some point in
future, fear of surgery and its
consequences, inconvenience of
administration; perceived side
effects. Those who chose surgery
did not choose other options such
as RT as they felt it was less
immediate treatment, less visible,
and indeﬁnite compared to
surgery. Some patients did not like
the daily treatment and
uncertainty of the external beam
RT
Anecdotes (others’ stories)
exerted strong sway over patients’
feelings about their own prostate
cancer, treatment preferences;
profound fear and uncertainty
(desire to receive treatment as
quickly as possible); inﬂuential
misconceptions about treatments;
perceived importance of ‘‘getting
the tumor out’’. Patients preferred
brachytherapy because the
treatment was directly in the
prostate, minimal side-effects and
minimal inconvenience while
others just accepted the
recommendation of the urologist
as they trusted him/her
None of patients explicitly
compared treatments in terms of
their relative likelihood of causing
side effects. 9/20 minimized
concerns about side effects
altogether, deeming these entirely
irrelevant to decision-making
process
Docherty [42] Yes, most have
received
treatment at
the time of
study
Radiation therapy,
surgery and hormonal
treatments
Thematic analysis NR Potential impact of treatment on
sex life
To avoid the impact of other
treatments on their sex life
NR
Elit [43] Yes Chemotherapy Inductive data
analysis
NA NR An important factor for most in
facilitating their treatment
process and forward-looking
approach was the kinds of support
they had available to them; imp
sources of information that
factored into treatment decision
were medical team, family
(particularly those that were
The authors noted that Impact of
side effects was not mentioned by
participants
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health care professionals or who
had had cancer experiences) and
medical literature. As the
participants had a recurrence,
their treatment experiences
impacted on their decision, as well
as their trust in their physician
and accepting the recommended
treatment
Holmboe [48] No The actual treatment
which had been chosen
by each participant
which could be
brachytherapy, external
beam radiation, radical
prostatectomy or
watchful waiting
A clinimetric
approach to
classify responses
in three
taxonomies
0% Radical Prostatectomy: risk of
incontinence, impotence and
invasiveness of procedure, long
recovery times, previous negative
treatment experiences and global
patients concerns. For external
beam radiation, dislikes were the
long duration and the concern for
radiation as well as the belief that
using this therapy precluded other
therapies in the future. For
brachytherapy, the main dislike
was the weakness of the evidence
supporting this approach. Men
rejected watchful waiting because
you need to combat tumor,
relative young age, fear of tumor
spreading, and physician
recommendation against watchful
waiting
Radical Prostatectomy: the most
commonly reported likes were
removal of the tumor and strength
of the evidence. For External beam
radiation: the likes was the track
record of therapy and
noninvasiveness. The most
common likes for brachytherapy
were short duration, limited
invasiveness and targeting the
treatment
NR
Husain [49] NR Surgery Framework
analysis
NR NR Physician recommendation,
experiences of family members
with certain treatments.
Speciﬁcally reasons for choosing
surgery included previous positive
experiences with surgery or
positive hospital experiences.
Reasons for choosing PET included
painful biopsies, not wanting
more surgical intervention, and
surgery could always be an option
if PET failed. It was important they
were able to carry on life as before
Participants didn’t consider what
impact decision would have on
social circumstances, being
burden on others
Kreling [50] Yes Chemotherapy Thematic analysis 0% Hurried appointments and talking
down to patient, not enough
speciﬁc info, and too much
written info, lack of family
support, negative experiences and
expectations, problems with
employment and insurance act as
barriers to chemotherapy use
Health status, good
communication with the
physician (able to express
preferences, fears and
expectations, enough time, family
included and information and
translation of materials), good
information about process of
chemotherapy and how side
effects will be managed, family
support, patient experiences with
chemo, death, expectations about
chemo and side effects and
employment and insurance
coverage promote chemotherapy
use
NR
O’Rourke [52] No Surgery, watchful Qualitative 0% NR Trust in physician, beliefs about NR
(continued on next page)
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Table 4 (continued)
First author & year
published
Previous
treatment
received
Type of treatment
studied
Type of analysis
used
Percentage/number
declining treatment
Factors associated with decline of
treatment
Factors associated with
acceptance of treatment
Other factors studied but not
important for acceptance or
refusal
waiting, radiation
therapy and hormonal
therapy
methods not
further speciﬁed
cure, positive experiences of
others and impact of treatment in
terms of side effects affected the
choice of treatment
Pieters [54] NR Surgery, radiation
therapy, chemotherapy
and hormonal therapy
Grounded theory
methodology
All women received
some treatment but
some declined a
second treatment,
the number of
which was NR
NR Obtaining information from
physician who the older woman
feels she can trust. Age of health
care provider also important.
Treatment experience of person
and other important persons are
important
NR
Sanders [56] Yes, most had
received
surgery
Chemotherapy and
radiotherapy
Grounded theory
methodology
Some patients
declined treatment
but the number is
NR
Fears of undertaking
chemotherapy, unclear beneﬁts,
not wanting to be a guinea pig,
other medical issues; Negative
preconceptions of chemotherapy,
uncertainty about the impact it
would have on his health and
whether it would be of beneﬁt,
concern that too much treatment
could be harmful to their
recovery; ‘‘just can’t go on going
through all of this’’; chemotherapy
was presented to patient as a
choice not as a ‘necessity’ which
might explain why he felt able to
reject it; having already agreed to
have radiotherapy (could have
strongly affected his decision not
to undertake chemo)
Patients who believed in cure
found treatment important
NR
Sharf [59] NR Radiation therapy,
chemotherapy or surgery
Grounded theory
methodology
All patients
declined treatment
The participants declined
treatments because they did not
trust their physician, based on
their own and important
experiences, belief in other non-
medical treatments, wanting to
avoid pain and prioritizing current
quality of life, not believing
treatment will be effective
NA, study focused on refusing
treatment only
NR
Sinding [27]b NR Hormone treatment,
surgery, chemotherapy,
radiation therapy
Grounded theory
methodology
27% Feeling that at their age, they
would not live forever, the
treatment increases risk of other
problems due to the presence of
comorbid conditions, cancer
treatments will exacerbate
symptoms of comorbid
conditions, fear of losing
independence and becoming
dependent on family members
NR NR
Sinding [26]b NR, ten were
within 1 year
of diagnosis
and four
between 1–
Surgery, radiation
therapy and
chemotherapy
Grounded theory
methodology
One out of 15
participants
declined all
treatment, other
participants
Caregiver roles for others,
knowledge from experience
(memories, emotions and
relationships), ﬁnancial costs, fear
of losing independence
Medical evidence, knowledge
from experience
NR
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2 years and
one between
2–3 years
declined some
treatments offered
(chemo, surgery or
radiation)
Ward-Smith [63] NR Radiation; patients have
received brachytherapy
Colaizzi’s
phenomenological
approach
0% Invasiveness and lengthy recovery
time of surgery, frequency of
hospital visits required for
traditional radiation which would
cost time and money, and would
require assistance from others to
attend appointments, inability to
lie ﬂat on traditional radiation
machine and experiences of
others who were experiencing
side effects of surgery and
traditional radiation
Individual lifestyle was most
important for choice of treatment
(chose brachytherapy as it would
interfere with their life the least).
Recommendations made by
television show also affected
decision
NR
White [64] NR Surgery, radiation
therapy or
brachytherapy
Qualitative content
analysis
100% Reasons for refusal included fear
of long-term side effects, the
experiences of others with
complementary and alternative
medicine and conventional
treatment, some of whom were
viewed as victims who had lost
their social and sexual identities,
and quality of life. Refusing
conventional treatment for
complementary and alternative
medicine gave a sense of control
and well-being. At times,
treatment did not match with the
spiritual beliefs of patient
NA, study focused on refusing
treatment only
NR
NR = not reported, NA = not applicable.
a Anchisi [28,29] reports on the same study.
b Sinding [26,27] reports on the same study.
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Table 5
Factors associated with cancer treatment decline or acceptance in quantitative studies.
First author &
year published
Previous
treatment
received
Type of treatment studied Type of
analysis
used
Percentage/number
declining Treatment
Factors associated with decline of
treatment
Factors associated with acceptance of
treatment
Other factors studied but
not important for
acceptance or refusal
Ashley [30] NR Surgery Descriptive 0% NA, all participants were asked about
the reasons why they chose a particular
type of surgery for their cancer
Personal reasons for accepting radical
cystectomy included fear of
incontinence, not wanting to do self-
catheterization, believing that self-
catheterization was too complicated and
the fear that the catheterization would
impact outdoor activity
NR
Cassileth [31] No Surgery or Hormonal
Therapy
Descriptive 0% Participants were recruited to the study
after they had selected surgical therapy
or hormonal therapy
The drug was chosen to avoid surgery;
success of treatment, convenience, and
physician’s advice were also important
factors. Those who chose surgery chose
convenience as the most important
reason, with the success of treatment
being another important reason
NR
Cykert [37] No Surgery Generalized
linear model
15/386 declined
surgery, and 42 did not
have surgery due to
comorbidities
Comorbid illness, religiosity (faith alone
can cure), perception of uncertain
diagnosis, belief that quality of life
would be worse because of surgery,
perception of lower-quality cancer
communication, anticipation of a worse
prognosis 1 year after surgery
Not studied, the study aim was to
explore why Blacks undergo surgery less
often than Whites
NR
Cyran [38] Treated with
mastectomy
or
lumpectomy
Surgery Descriptive 0% All participants had received cancer
treatment (that was inclusion criteria)
and where asked why they selected
either mastectomy or lumpectomy
Reasons for choosing mastectomy over
lumpectomy: fear of recurrence,
wanting to get treatment over with, and
physician recommendation. Reasons for
choosing Lumpectomy over
mastectomy: keeping the breast,
equivalent survival, and physician
recommendation
NR
Diefenbach [41] No All types of treatment Descriptive 0% NA, patients were asked why they had
chosen their current cancer treatment
Reasons for choosing external beam
radiation therapy were that the
treatment was less painful, less invasive
and fewer side effects and more
convenient than surgery. Reasons for
choosing surgery were that it would
offer the best chance of cure, and
patients knew somebody who had
received the same treatment and they
saw their disease as more serious
NR
Gorin [44] No Active surveillance Descriptive 0% Concern about incontinence and
impotence related to treatments
‘‘Doctor thought it was a reasonable
alternative’’, ‘‘I felt I could still be cured
with treatment if my cancer
progressed’’, ‘‘ I have researched the
alternatives and this one seems the best
for the type of prostate cancer I have’’
NR
Gwede [45] No Radical Prostatectomy or
brachytherapy
Logistic
regression
0% NA, participants were asked why they
had chosen their treatment, all had
received treatment
Chance of cure a treatment offered,
treatment invasiveness, avoidance of
the side effects of other treatments,
painfulness, convenience of treatment,
avoidance of surgery
NR
Hall [46] NR Radical prostatectomy,
brachytherapy as
monotherapy (BT) or
Descriptive For 14 patients the
treatment received
was unknown
NA, all participants are asked to choose
between 2 treatment regiments
43% of BT monotherapy patients choose
this treatment because it was the best
procedure to cure the cancer, and 60%
NR
210
M
.T.E.Puts
et
al./Cancer
Treatm
ent
R
eview
s
41
(2015)
197–
215
brachytherapy with
external beam boost
indicated this for the BT plus external
beam boost group. 40% chose BT
because of the side effect proﬁle as most
important reason and 26% in the BT plus
external beam boost group
Hardy [47] Yes, 48% had
previous RT
and 43% had
previous
surgery for
their prostate
cancer
Hormonal therapy Descriptive NA NA, all participants are currently
receiving hormonal therapy for their
disease
The most important factor for choosing
their hormonal therapy (patients were
using several different hormonal
regimens) were: 39% wanted control of
their disease, 31% wanted the highest
chance to outlive their disease and 12%
wanted to maintain an active life as long
as possible, 8% chose it as the therapy
has been proven to improve survival, 4%
choose it for being the most powerful
therapy, 3% choose it for symptom relief,
and 3% chose it as it has few side effects
NR
Lim [51] NR Chemo radiation Descriptive 50% Reasons for refusing surgery included
desire to avoid a permanent stoma, and
fear of operative morbidity or mortality
NA, chart review of reasons for decline NA
Petrisek [53] NR, patients
had
nonrecurring
disease
Surgery, radiation therapy,
chemotherapy and
hormonal therapy
Logistic
regression,
Chi Square
tests
NR Transportation issues affected the
choice of older women, ﬁnancial issues
were important for those without
private insurance, physician
recommendation, not having the
problem return, family and experience
of others important in treatment
selection
For older women fear of
recurrence, physical
aspects of treatment and
responsibilities were
signiﬁcantly less
important as compared to
those younger
Richert-Boe [55] NR Radical prostatectomy or
radiotherapy
Descriptive Seven of the 66 African
American men and 12
of the 149 White
American men offered
treatment with
curative intent
declined it
Advanced age, low-risk disease, desire
to try alternative therapies
NA, the study focused on comparing if
there were racial differences in why
African men compared to white men
received less treatment with curative
intent
NA
Sandison [57] NR Tamoxifen alone vs. local
excision and tamoxifen vs.
modiﬁed radical
mastectomy and
tamoxifen vs. local
excision, radiation therapy
and tamoxifen
Descriptive NA NA, participants were asked why they
chose their treatment for their breast
cancer
Physician recommendation, to avoid the
‘‘trouble’’ of local excision with radiation
therapy
NR
Schulman [58] Yes, currently
receiving
LHRH agonists
Hormonal therapy Descriptive 0% Not studied, all patients were asked
about hormone treatment preferences
Trust in physician, ability of treatment
to lower testosterone levels, simpler and
fewer injections, low levels of
discomfort or pain, higher quality of life,
fewer reminders of the disease, ability to
maintain their lifestyle during
treatment by allowing for more ability
to undertake activities w/o restriction
NR
Tang [60] No Radiation Logistic
regression
0% Not studied, patient preference for
different radiation schedules were
studied
39 Gy in 13 daily fractions: longer
survival advantage offered, better local
control and less psychological distress.
17 Gy in 2 fractions: shorter treatment
duration, lower cost of treatment and
better symptom control
NR
Tang [61] Some patients
have a history
of other
Surgery, hormonal
therapy, radiation therapy
and chemotherapy
Descriptive 4 patients declined all
treatments offered
Those who declined surgery and choose
PET did it because of feelings of
unﬁtness, refusal to have surgery, and
Those who choose surgery choose it
because of perceptions of more
favorable outcomes, feeling the need of
NR
(continued on next page)
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ticipants followed the treatment recommended by their physician.
This review also showed that many of the reasons which could lead
the patient to either accept or decline treatment were the same
factors (e.g. trust in physician could be high in which the treatment
was accepted or low and this could lead to decline of treatment).
Very few studies have investigated age differences in the reasons
for accepting or declining treatment between the young old and
older old study participants, but there were some subtle differ-
ences (e.g. older adults declined more often for reasons of comor-
bidities and transportation issues). There was only one study by
Hussain et al. [49] with a mean age > 80 years. As beneﬁts and risks
of treatment are different for a 65 and 85 year old, and with the
rapidly increasing octogenarian population in many countries
around the world, it is important to study the oldest old as well
to allow development of interventions to support treatment deci-
sion-making for all older patients. There were no studies compar-
ing factors important to accept or decline cancer treatments across
cancer types, and only one study focused on differences by stage.
Despite the emphasis on shared-decision making in Western
countries, studies showed that most older adults accepted the
treatment recommendation from their oncologist. A recent system-
atic review showed that the training of health care providers in
shared decision making varies widely [66]. It is thus very important
that health care providers in the oncology setting involved in the
treatment decision-making process realize their impact on the
patient’s cancer treatment decision and thus cancer treatment out-
come and this should be included in health care professionals train-
ing for decision making with older adults. The communication gap
between oncologist and patient has been known for some time [67].
The quality of communication impacts a patient’s quality of life and
his/her awareness of the prognosis [68,69]. A recent Cochrane
meta-analysis showed that there are several existing interventions
to improve patient-oncology health care provider communication,
but it is also noted that the long-term effect (e.g. sustainability) is
not yet known [70]. No subgroup analysis examining the effect
for older patients was conducted as part of this Cochrane meta-
analysis and due to the prevalence of classical geriatric factors such
as cognitive changes and sensory impairment, it is possible that
interventions need to be tailored further to suit the needs of the
elderly cancer population, hence this should be studied formally.
As there is no measurement tool to measure reasons for accep-
tance or declining of cancer treatment, most studies had developed
a measurement tool speciﬁc for their study and almost no study
had actually included the tool in the publication. Similarly, for
the qualitative studies almost no study had included the inter-
viewer/moderator topic guide. Furthermore, most of the studies
were not aimed at speciﬁcally examining reasons why older adults
accepted or declined the recommended treatment. Thus it is
unclear if factors that were not reported in the studies included
in this review were really not important or just not studied until
now. Important geriatric health conditions such as cognition and
sensory impairment were not reported. Furthermore, few studies
reported on the role of comorbid conditions as a reason to decline
treatment. Lastly, it has been reported that older adults may have
lower levels of health literacy [71–73], and this could be expected
to impact why older adults accept or decline cancer treatment, and
thus should be studied. Furthermore, with the development of
more oral cancer treatments particularly for frail older adults and
with the aging of the population, there will be an increase in the
number of older adults facing a cancer treatment decision which
is different from the ones studied in the included studies. It is thus
important that larger studies of higher methodological quality are
conducted, particularly taking into account classical geriatric fac-
tors such as comorbidities and cognition, as well as health literacy
and populations other populations than Caucasians as most studies
Table 6
Summary of factors inﬂuencing the decision to accept/decline active treatment.
Reasons for acceptance of active cancer treatment Qualitative studies (18 studies) Quantitative studies (20 studies)
Treatment related factors
Treatment convenience 5 studies [34,40,48,49,63] 11 studies [30,31,38,41,45,53,57,58,60–62]
Expectations about side effects 10 studies [29,32–34,40,42,48–50,52] 6 studies [30,45–47,58,62]
Treatment success rate 4 studies [26,33,40,48] 10 studies [31,38,41,44,45,47,53,58,60–62]
Physician related factors
Trust in physician 10 studies [29,34,35,39,40,43,50,52,54] 3 studies [31,44,58]
Treatment recommended by oncologist 7 studies [29,33–35,43,48,49] 5 studies [31,38,44,53,57]
Information received about treatment 4 studies [29,43,50,63]
Patient related factors
Awareness of the disease and prognosis and thus the necessity
of treatment/wanting to get rid
of cancer/if it is cancer it should be treated/belief about cure
9 studies [28,29,32–34,39,40,48,52,56] 5 studies [38,41,46,47,61]
Treatment experience of family members/friends 9 studies [26,34,39,40,43,49,52,54,54] 3 studies [41,53,61]
Wanting to live as long as possible/continue current lifestyle 4 studies [28,33,49,63] 3 studies [30,47,58]
Previous personal positive treatment experience/hospital experience 6 studies [26,43,49,50,54,54]
Family support 2 studies [28,50]
Pressure of family members to have treatment 1 study [32]
Not wanting to be a burden by leaving illness untreated 1 study [33]
Reasons for decline of active cancer treatment Qualitative studies (18 studies) Quantitative studies (20 studies)
Treatment related factors
Expectations about side effects 12 studies
[32,34,36,39,40,42,48,50,56,59,63,64]
4 studies [37,44,51,61]
Physician related factors
Unclear beneﬁts of treatment 6 studies [32,34,40,48,50,56,59] 1 study [37]
Distrusting physician/poor communication/information about treatment 2 studies [50,56,59] 1 study [37]
Patient related factors
Treatment experience of family members and friends 7 studies [26,34,36,39,40,63,64]
Feeling high risk due to comorbidities/other medical issues 3 studies [27,34,56] 4 studies [19,37,51,61]
Quality of life and comfort is most important at their age/feeling too old for
treatment
3 studies [27,34,59] 3 studies [19,55,61]
Belief in non-conventional treatments 2 studies [59,64] 2 studies [19,55]
Financial reasons 3 studies [26,50,63] 1 study [19]
Wanting to avoid becoming dependent on others/fear of losing independence 3 studies [26,27,33,63]
Personal negative treatment experiences 2 studies [48,50]
Transportation issues 2 studies [28,63]
Not wanting to be a guinea pig 1 study [56]
Care giving responsibilities 1 study [26]
Belief that faith alone can cure disease 1 study [37]
Feeling asymptomatic 1 study [61]
Depression 1 study [19]
Having low-risk disease 1 study [55]
Lack of family support 1 study [50]
Fields have been left blank where no studies assessed a speciﬁc factor (e.g. previous positive experience in quantitative studies).
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adults declined treatment is important to determine if interven-
tions to enhance the quality of the treatment decision-making pro-
cess are warranted. However, only two small qualitative studies
focused on older adults who declined cancer treatment [59,64]. It
is thus important that more studies explore this issue using larger
samples. More importantly, a validated measurement tool to reli-
ably assess reasons for accepting or declining cancer treatment
should also be developed. Patients can make fully informed and
autonomous decisions to decline treatment. However, if treat-
ments are declined because of reasons of distrusting the physician,
feeling at high risk due to age or communication, poor communi-
cation and inadequate information about the treatment risks and
beneﬁts received, this should be addressed as those patients are
at risk for potentially avoidable poorer outcomes of cancer. Fur-
thermore, as almost all studies have focused on treatment deci-
sions for breast and prostate cancer, very little is known about
which factors are important reasons to accept or decline treatment
for other cancers common in older adults, such as lung, colorectal
or hematological malignancies. Additionally, as these studies have
only included women or men, it is not known if there are
differences based on sex and this may be important when
developing interventions to enhance the quality of the treatmentdecision-making process. Further studies are needed to examine
treatment decision-making in participants diagnosed with other
cancers.
This systematic review has several strengths. Although there
had been previous narrative reviews on treatment decision making
in older adults, none used a systematic approach to appraise the
literature [21–23]. In this review, two independent reviewers
reviewed abstracts and abstracted the data. We included ten dat-
abases and four languages, we included both qualitative as well
as quantitative studies and no study was excluded based on the
quality assessment scores. However, this review also has limita-
tions. As in any review, the ﬁndings are limited by the methodolog-
ical quality of the included studies. And many of the studies
included were conducted some time ago and as the reporting stan-
dards were not as developed as they are today, there were few
studies of excellent methodological quality. We were not able to
calculate how many patients refused for a particular reason, only
report the number of studies reporting a particular reason due to
a lack of details included in the manuscript. No meta-analysis
was conducted as the studies were too heterogeneous with regard
to study population and data collected.
In conclusion, the reasons why older adults with cancer
accepted or declined treatment varied considerably. Further stud-
214 M.T.E. Puts et al. / Cancer Treatment Reviews 41 (2015) 197–215ies using large representative samples with different cancer types
and race and exploring treatment decision making incorporating
health literacy and comorbidity are needed.
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